Exploring the theranostic role of Lu-177 herceptin in HER2 expressing breast cancer: Preliminary studies on comparison with F-18-FDG PET/CT
490 Objectives: Herceptin is an anti HER2 antibody and often used for the treatment of
HER2 primary and metastatic disease. Lu-177 herceptin may prove as a potential …
HER2 primary and metastatic disease. Lu-177 herceptin may prove as a potential …
[HTML][HTML] Lu-177-Herceptin: A Potential Radioimmunoconjugate for Treatment of HER2 Metastatic Breast Cancer
P Bhusari, J Shukla, R Vatsa, G Singh… - World Journal of …, 2016 - ncbi.nlm.nih.gov
Results: Imaging using Lu-177-trastuzumab demonstrated promising results. The
radioimmunoconjugate showed localization in primary and metastatic lesions specifically in …
radioimmunoconjugate showed localization in primary and metastatic lesions specifically in …
Evaluating the therapeutic potential of 188Re-HYNIC-trastuzumab (Herceptin) for human breast cancer in the animal model
Y Wu, I Tang, C Liu, T Luo, W Lin - 2009 - Soc Nuclear Med
1590 Objectives Her-2/neu protein over expression has been identified in 10%~ 34% of
invasive breast cancers. Trastuzumab (Herceptin) is a humanized IgG1 monoclonal …
invasive breast cancers. Trastuzumab (Herceptin) is a humanized IgG1 monoclonal …
177Lu labeling of Herceptin and preclinical validation as a new radiopharmaceutical for radioimmunotherapy of breast cancer
INTRODUCTION: In the present study, Herceptin was labeled with lutetium-177 via DOTA,
and the necessary preclinical quality control tests (in vitro and in vivo) were performed to …
and the necessary preclinical quality control tests (in vitro and in vivo) were performed to …
Radiolabeling of Herceptin with 99mTc as a Her2 Tracer
Introduction: Trastuzumab is a monoclonal antibody that is used in treating breast cancer.
We labeled this monoclonal antibody with Technetium-99m and performed in vitro and in …
We labeled this monoclonal antibody with Technetium-99m and performed in vitro and in …
Accuracy of [68Ga] ABY-025 PET/CT for determination of HER2-expression in metastatic breast cancer
J Sörensen, I Velikyan, D Sandberg, H Olofsson… - 2015 - Soc Nuclear Med
156 Objectives Human epidermal growth factor 2 (HER2) is overexpressed in 20% of breast
cancers and anti-HER2 therapy greatly improves survival of patients. Imaging of HER2 could …
cancers and anti-HER2 therapy greatly improves survival of patients. Imaging of HER2 could …
Molecular imaging of HER2 expression in breast cancer patients using the [99mTc] Tc-labeled small peptide
JB Ardakani, SM Abedi, A Mardanshahi, L Shojaee… - Clinical Breast …, 2023 - Elsevier
Purpose The accurate determination of human epidermal growth factor receptor 2 (HER2)
status can predict response to treatment with HER2-targeted therapy for HER2-positive …
status can predict response to treatment with HER2-targeted therapy for HER2-positive …
Development of Lu‐177‐trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients
P Bhusari, R Vatsa, G Singh, M Parmar… - … Journal of Cancer, 2017 - Wiley Online Library
HER2/neu is over expressed in 20–25% of breast cancers. HER2 breast cancers are
aggressive and are associated with poor prognosis. The aim of this study was to develop the …
aggressive and are associated with poor prognosis. The aim of this study was to develop the …
Evaluating the potential of 188Re-HYNIC-trastuzumab (Herceptin) as a novel radiopharmaceutical for breast cancer treatment
YL Wu, CJ Liu, IC Tang, TY Luo, WJ Lin - 2008 - Soc Nuclear Med
2126 Objectives: Her-2/neu protein over expression has been identified in 10%~ 34% of
invasive breast cancers. Trastuzumab (Herceptin) is a humanized IgG1 monoclonal …
invasive breast cancers. Trastuzumab (Herceptin) is a humanized IgG1 monoclonal …
[HTML][HTML] 99mTc‑labeled single-domain antibody for SPECT/CT assessment of HER2 expression in diverse cancer types
B Altunay, A Goedicke, OH Winz, F Hertel… - European Journal of …, 2023 - Springer
The expression status of human epidermal growth factor receptor 2 (HER2) in cancer
predicts response to HER2-targeted therapy. Therefore, its accurate determination is of …
predicts response to HER2-targeted therapy. Therefore, its accurate determination is of …